| Autor: |
Perabo FG; Klinik und Poliklinik für Urologie, Universitätsklinikum, Sigmund-Freud-Strasse 25, 53105 Bonn. perabo@lycos.com, von Löw EC, Siener R, Ellinger J, Müller SC, Bastian PJ |
| Jazyk: |
němčina |
| Zdroj: |
Der Urologe. Ausg. A [Urologe A] 2009 Mar; Vol. 48 (3), pp. 270-1, 274-83. |
| DOI: |
10.1007/s00120-008-1929-5 |
| Abstrakt: |
Prostate cancer patients increasingly use complementary and alternative medicines to support the body's immune system in addition to conventional treatment to minimize morbidity associated with conventional treatment, to enhance the quality of life, and ultimately in the hope to cure cancer when conventional treatment fails. As there is a large variety of phytomedicines promoted as potential treatment for prostate cancer, the aim of this review was to differentiate between preventive and therapeutic approaches and evaluate which phytochemicals might be suited for therapy of prostate cancer. Therefore, preclinical in vitro and in vivo data as well as clinical trials with phytosubstances such as genistein, lycopene, epigallocatechin gallate, resveratrol, and mistletoe were assessed. The presented data show that at present there is no clinical evidence that phytochemicals might have a therapeutic use in prostate cancer in relation to reduction of tumor progression or improved survival. The question about an improved immune function or quality of life remains open. Potentially the use of phytochemicals could play a role in a preventive setting. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink